辰光医疗发布业绩预告，预计2025年全年归属净利润亏损5300万元至6600万元。 公司公告汇总2025年年度业绩预告公告 截至2026年1月29日收盘，辰光医疗(920300)报收于14.99元，下跌1.51%，换手率2.55%，成交量1.69万 手，成交额2558.3万元。 当日关注点 交易信息汇总资金流向 1月29日主力资金净流出128.01万元，占总成交额5.0%；游资资金净流出196.64万元，占总成交额 7.69%；散户资金净流出21.33万元，占总成交额0.83%。 业绩披露要点业绩预告 上海辰光医疗科技股份有限公司预计2025年度归属于上市公司股东的净利润为-5,300万元至-6,600万 元，较上年同期亏损有所收窄。本期业绩变动主要原因系公司营业收入下降，受磁共振整机行业竞争加 剧影响，1.5T磁共振系统销售收入减少；同时7.0T磁共振系统因属科研用小众产品，2025年未实现销 售，进一步影响收入。公告所载财务数据为初步核算结果，未经审计，最终数据以2025年年度报告为 准。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投 ...

辰光医疗2025年三季报显示，前三季度公司主营收入6774.26万元，同比下降21.33%；归母净利 润-1933.07万元，同比下降21.77%；扣非净利润-2148.9万元，同比下降3.01%；其中2025年第三季度， 公司单季度主营收入2038.99万元，同比下降29.57%；单季度归母净利润-451.3万元，同比上升3.33%； 单季度扣非净利润-528.12万元，同比上升9.47%；负债率48.48%，投资收益23.9万元，财务费用385.49 万元，毛利率49.73%。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，辰光医疗发布业绩预告，预计2025年全年归属净利润亏损5300万元至6600万元。 公告中解释本次业绩变动的原因为： 2025年度公司营业收入有所下降,公司营收增长仍受磁共振整机行业竞争格局影响。2025年中国磁共振 系统市场保持持续竞争态势,特别是头部企业针对集采"带量采购,以量换价"的政策,医学影像设备行业中 标价同比大幅下降,因此公司的1.5T磁共振系统销售收入受到影响。此外公司7.0T ...

Core Viewpoint - Chuangguang Medical announced the completion of its fundraising project "Research and Custom Superconducting Magnet Development Project" by December 18, 2025, and the funds have been fully utilized as per regulations [2] Group 1 - The company has completed the construction of the fundraising project and it has reached the predetermined usable status [2] - The remaining balance of the fundraising account, amounting to 947,791.67 yuan (including interest income), has been transferred to the company's general bank account for working capital supplementation [2] - The special fundraising account was officially closed on January 14, 2026, to facilitate the management of the raised funds [2]

Group 1 - The core point of the article is that Chen Guang Medical (920300) experienced a significant increase of 12.56% in its stock price, with a trading volume of 2.75 billion yuan and a turnover rate of 24.13% on the day [1][2] - Institutional investors net bought 3.53 million yuan, while brokerage seats collectively net sold 12.28 million yuan [1][2] - The stock was listed on the exchange due to its high turnover rate, with the top five brokerage seats contributing a total transaction volume of 63.01 million yuan, where the buying amount was 27.13 million yuan and the selling amount was 35.88 million yuan, resulting in a net sell of 8.75 million yuan [2] Group 2 - The top buying brokerage seat was an institutional specialized seat, which bought 6.28 million yuan and sold 2.75 million yuan, resulting in a net purchase of 3.53 million yuan [2] - The second largest buying seat was Dongfang Securities, which bought 6.15 million yuan without any selling [2] - The selling activities were led by CITIC Securities, which sold 5.45 million yuan while buying only 0.52 million yuan [2]

Group 1 - The core point of the article is that Changuang Medical (920300) was featured on the trading leaderboard due to a significant trading volume and turnover rate on January 5, 2026, with a turnover rate of 24.13% and a transaction amount of 275 million yuan [1][3]. - The total number of shares traded for Changuang Medical on that day was approximately 16.06 million shares [1]. - The leading buyer was an institutional investor, purchasing approximately 6.28 million yuan worth of shares, while the main seller was CITIC Securities, selling around 5.45 million yuan [1][2]. Group 2 - The trading data shows that the top three buying institutions included Dongfang Securities and Guotou Securities, with buying amounts of approximately 6.15 million yuan and 4.91 million yuan, respectively [2]. - The selling data indicates that the top three selling institutions were CITIC Securities, Jianghai Securities, and Guojin Securities, with selling amounts of approximately 5.45 million yuan, 5.43 million yuan, and 5.24 million yuan, respectively [2]. - The overall trading activity reflects a high level of interest in Changuang Medical, as evidenced by the substantial turnover and participation from both institutional buyers and sellers [1][2].

Core Viewpoint - The A-share market is experiencing a localized surge in the controlled nuclear fusion concept, with notable stocks such as Wangzi New Materials hitting the daily limit up and Libet approaching the limit up [1] Group 1: Market Performance - Wangzi New Materials has reached the daily limit up, indicating strong investor interest [1] - Libet has seen significant price movement, nearing the daily limit up [1] - Other companies such as Guoguang Electric, Guoji Heavy Industry, Hezhuan Intelligent, Changfu Shares, and Chenguang Medical are also experiencing upward trends [1] Group 2: Industry Outlook - The 2026 Nuclear Fusion Energy Technology and Industry Conference is scheduled to take place from January 16 to 17, 2026, in Hefei, Anhui [1] - According to a report by Zheshang Securities, the global nuclear fusion equipment market is expected to reach an average annual scale of 266 billion yuan by 2035 [1]

Core Insights - The medical device sector experienced a slight increase of 0.01% on October 23, with Chen Guang Medical leading the gains [1] - The Shanghai Composite Index closed at 3922.41, up 0.22%, while the Shenzhen Component Index also rose by 0.22% to 13025.45 [1] Medical Device Sector Performance - Chen Guang Medical (code: 920300) saw a significant rise of 16.01%, closing at 19.20 with a trading volume of 126,000 shares and a transaction value of 230 million [1] - Other notable gainers included Shuoshi Biology (code: 6628899) with a 7.07% increase, closing at 75.38, and Kangwei Century (code: 688426) which rose by 5.17% to 28.70 [1] - Conversely, the sector also had some decliners, with Toukeng Life (code: 300642) dropping by 6.19% to 24.26, and Rejing Biology (code: 688068) decreasing by 4.07% to 165.15 [2] Capital Flow Analysis - The medical device sector experienced a net outflow of 542 million from institutional investors, while retail investors saw a net inflow of 373 million [2] - Notable net inflows from retail investors were observed in several companies, including Sainuo Medical (code: 688108) with a net inflow of 1.33 billion [3] - The overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors remain active in the market [2][3]

证券代码：430300 证券简称：辰光医疗 公告编号：2025-116 上海辰光医疗科技股份有限公司 投资者关系活动记录表 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 一、 投资者关系活动类别 □特定对象调研 √业绩说明会 □媒体采访 □现场参观 □新闻发布会 □分析师会议 □路演活动 1、董事长、总经理：王杰 先生 2、董事、副总经理：王为 先生 3、董事会秘书：于玲 女士 4、财务总监：郑云 女士 三、 投资者关系活动主要内容 本次投资者关系活动的主要问题及公司对投资者相关问题的回复如下： □其他 二、 投资者关系活动情况 活动时间：2025 年 9 月 19 日 15:00 至 17:00 活动地点：本次活动采用网络远程方式举行，投资者登录"全景路演"网站 "投资者关系互动平台"（https://ir.p5w.net）；或关注微信公众号"全景财经"； 或下载全景路演 APP，参与本次互动交流。 参会单位及人员：通过网络远程方式参与"2025 年上海辖区上市公司集体 接待日暨中报业绩说明会活动" ...

Core Viewpoint - The company is transitioning from being a core component supplier for MRI to a full MRI system supplier, aiming to enhance its market presence and clinical value in the medical imaging industry [1] Group 1: Strategic Transition - The company is strategically transforming into an MRI system supplier, moving beyond just core component supply [1] - The company will debut as an MRI manufacturer at the China International Medical Equipment Fair (CMEF) in April 2025, showcasing the Farol 1.5T superconducting MRI system and other advanced imaging technologies [1] Group 2: Product Development and Market Entry - The company has received medical device registration for its DR equipment and is in the market promotion phase, participating in centralized procurement bids in several provinces [1] - The company did not win bids in Henan and Jiangsu provinces, while the project in Anhui has not yet been opened for bidding [1] - The CT equipment has completed prototype production and is currently undergoing registration review, with plans to advance to market in the first half of 2026 [1]

证券代码：430300 证券简称：辰光医疗 公告编号：2025-115 上海辰光医疗科技股份有限公司 关于召开 2025 年第三次临时股东会通知公告（提供网络投票） 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开基本情况 （一）股东会届次 本次会议为 2025 年第三次临时股东会。 （二）召集人 本次股东会的召集人为董事会。 上海辰光医疗科技股份有限公司（以下简称"公司"）于 2025 年 9 月 17 日召开第五届董事会第二十三次会议，审议通过了《关于召开 2025 年第三次临 时股东会通知的议案》。 （三）会议召开的合法合规性 本次股东会的召集、召开符合《公司法》有关法律、行政法规、部门规章、 规范性文件和《公司章程》的规定。 （四）会议召开方式 公司股东应选择现场投票、网络投票中的一种方式，如果同一表决权出现 重复投票表决的，以第一次投票表决结果为准。 （五）会议召开日期和时间 1、现场会议召开时间：2025 年 10 月 15 日下午 15:00。 2、网络投票起止时间：2025年 ...